Evidence map›Paper›PMID 39898787›Full record

ArticleChembiochem : a European journal of chemical biology2025

Proteome-Wide Profiling of Olaparib Interactors Using a Biotinylated Photoaffinity Probe.

Femke L A M van der Heijden, Suzanne A Weijers, Onno Bleijerveld, Katarzyna W Kliza, Michiel Vermeulen, Dmitri V Filippov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Proteome-Wide Profiling of Olaparib Interactors Using a Biotinylated Photoaffinity Probe.Chembiochem : a European journal of chemical biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Femke L A M van der HeijdenLeiden Institute of Chemistry, Leiden University Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0009-0007-9796-1826
Suzanne A WeijersDivision of Molecular Genetics, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-0269-5961
Onno BleijerveldDivision of Molecular Genetics, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Katarzyna W KlizaDepartment of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Geert Grooteplein 28, 6525 GA, Nijmegen, The Netherlands.
Michiel VermeulenDivision of Molecular Genetics, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Dmitri V FilippovLeiden Institute of Chemistry, Leiden University Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-6978-7425

Funding

Dutch Research Council OCENW.KLEIN.497
6 · The paper itself

Abstract

Olaparib is a widely used PARP inhibitor for the treatment of BRCA-mutated cancers. To comprehensively understand the drug's clinical impact, measuring its interactions with intended on- and off-targets is crucial. In this study, olaparib's on- and off-targets were profiled using photoaffinity labeling, a powerful, proteome-wide method for studying the direct interactions between a drug and its protein targets. A novel photoaffinity probe was designed and used in a proteomic screening to discover novel targets of olaparib in the human proteome. The probe, incorporating a pre-installed biotin group, bypasses the limitations of using a copper(I)-catalyzed click reaction in cell lysates for reporter group conjugation and revealed a broad range of olaparib interactors, including previously unreported proteins, in a quantitative mass spectrometry-based proteomic screening using HeLa whole cell lysate. This study contributes to our current understanding of the pharmacology of olaparib and provides a valuable tool for elucidating drug interactors within cell lysates, potentially guiding the development of more targeted therapeutics with fewer off-targets.

Indexed as

Photoaffinity LabelsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProteomeBiotinBiotinylationHeLa CellsHumansProteomicsBiotinolaparibPhotoaffinity LabelsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProteomeChemical ProteomicsOlaparibPARP inhibitorsPhotoaffinity labeling

Identifiers

PMID39898787
PMCPMC11907390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.